BACKGROUND: In the general population, 27% of adults have the metabolic syndrome (MetS) and is associated with increased mortality. Similar data are not available for a heart failure (HF) population. This study sought to determine the prevalence of the MetS and its effect on mortality in a HF population. METHODS AND RESULTS: Patients (n = 886) discharged from the hospital with a primary diagnosis of HF were retrospectively identified. Demographic, clinical, and laboratory data were extracted by chart review. The MetS was defined according to National Cholesterol Education Program Expert Panel criteria with a body mass index >or=30 kg/m(2) substituted for increased waist circumference. Mortality data were acquired by query of the National Death Index, with a median follow-up of 856 days. Data were available to evaluate for the presence or absence of MetS in 71% (n = 625). The prevalence of MetS in this cohort was 68%. MetS was most common in Hispanics (79%) compared with whites (70%) and blacks (61%, P = .003). Mortality was lower in those with MetS (44%) compared with those without (58%, unadjusted HR 0.67 [95% CI, 0.53-0.85]). In a fully adjusted model, there was still a significantly lower risk of mortality in those with MetS (adjusted HR 0.73 [95% CI, 0.56-0.94]). CONCLUSIONS: In a cohort hospitalized with HF, the prevalence of MetS exceeds that of the general population, and unlike the general population, MetS is associated with a lower mortality.
BACKGROUND: In the general population, 27% of adults have the metabolic syndrome (MetS) and is associated with increased mortality. Similar data are not available for a heart failure (HF) population. This study sought to determine the prevalence of the MetS and its effect on mortality in a HF population. METHODS AND RESULTS:Patients (n = 886) discharged from the hospital with a primary diagnosis of HF were retrospectively identified. Demographic, clinical, and laboratory data were extracted by chart review. The MetS was defined according to National Cholesterol Education Program Expert Panel criteria with a body mass index >or=30 kg/m(2) substituted for increased waist circumference. Mortality data were acquired by query of the National Death Index, with a median follow-up of 856 days. Data were available to evaluate for the presence or absence of MetS in 71% (n = 625). The prevalence of MetS in this cohort was 68%. MetS was most common in Hispanics (79%) compared with whites (70%) and blacks (61%, P = .003). Mortality was lower in those with MetS (44%) compared with those without (58%, unadjusted HR 0.67 [95% CI, 0.53-0.85]). In a fully adjusted model, there was still a significantly lower risk of mortality in those with MetS (adjusted HR 0.73 [95% CI, 0.56-0.94]). CONCLUSIONS: In a cohort hospitalized with HF, the prevalence of MetS exceeds that of the general population, and unlike the general population, MetS is associated with a lower mortality.
Authors: Allison M Pritchett; Anita Deswal; David Aguilar; John P Foreyt; Wenyaw Chan; Douglas L Mann; Christie Ballantyne; Biykem Bozkurt Journal: J Obes Weight Loss Ther Date: 2012-03-15
Authors: Stephan von Haehling; Mitja Lainscak; Wolfram Doehner; Piotr Ponikowski; Giuseppe Rosano; Jens Jordan; Piotr Rozentryt; Mathias Rauchhaus; Rostislav Karpov; Vsevolod Tkachuk; Yelena Parfyonova; Andrey Y Zaritskey; Eugeniy V Shlyakhto; John G Cleland; Stefan D Anker Journal: J Cachexia Sarcopenia Muscle Date: 2010-12-17 Impact factor: 12.910
Authors: Omar Asghar; Ahmed Al-Sunni; Kaivan Khavandi; Ali Khavandi; Sarah Withers; Adam Greenstein; Anthony M Heagerty; Rayaz A Malik Journal: Clin Sci (Lond) Date: 2009-05 Impact factor: 6.124